J9061 Amivantamab - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Amivantamab

Brand Name:

Rybrevant

Strength:

2mg

HCPCS:

J9061

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Monoclonal Antibody

Minor Drug Class:

EGFR, MET

Oral (Y/N):

No

FDA Approval Year:

2021

FDA Discontinuation Year:

CMS Effective Date:

Jan. 26, 2022

CMS Discontinuation Date:

Status:

In Use